Malignant glioma is the most common brain tumor with 16 000 new cases diagnosed annually in the United States. We performed a systematic large-scale transcriptomics data mining study of 9783 tissue samples from the GeneSapiens database to systematically identify genes that are most glioma-specific. We searched for genes that were highly expressed in 322 glioblastoma multiforme tissue samples and 66 anaplastic astrocytomas as compared with 425 samples from histologically normal central nervous system. Transcription cofactor HES6 (hairy and enhancer of split 6) emerged as the most glioma-specific gene. Immunostaining of a tissue microarray showed HES6 expression in 335 (98.8%) out of the 339 glioma samples. HES6 was expressed in endothelial cells of the normal brain and glioma tissue. Recurrent grade 2 astrocytomas and grade 2 or 3 oligodendrogliomas showed higher levels of HES6 immunoreactivity than the corresponding primary tumors. High HES6 mRNA expression correlated with the proneural subtype that generally has a favorable outcome but is prone to recur. Functional studies suggested an important role for HES6 in supporting survival of glioma cells, as evidenced by reduction of cancer cell proliferation and migration after HES6 silencing. The biological role and consequences of HES6 silencing and overexpression was explored with genome-wide analyses, which implicated a role for HES6 in p53, c-myc and nuclear factor-jB transcriptional networks. We conclude that HES6 is important for glioma cell proliferation and migration, and may have a role in angiogenesis.
Introduction
Malignant glioma is the most common brain cancer with B16 000 new cases diagnosed annually in the United States. High-grade malignant gliomas comprise of the World Health Organization (WHO) grade IV brain tumors, including glioblastoma multiforme (GBM) and its variants, and the WHO grade III tumors (anaplastic forms of astrocytoma, oligodendroglioma and oligoastrocytoma). GBM is the most common primary brain tumor in adults. Primary GBM forms de novo without a previous history of a low-grade disease, whereas secondary GBM progresses from previously diagnosed low-grade glioma. Patients with newly diagnosed GBM have a median survival of B1 year, and GBMs usually respond relatively poorly to chemotherapy and radiotherapy Kleihues, 2007, 2009 ; Kumar et al., 2008) . Tumor recurrence is common after current treatments, and the disease follows a fatal course in virtually all patients.
Recently, The Cancer Genome Atlas (TCGA) Project was launched to comprehensively profile 500 GBM samples on several microarray platforms, such as gene exon, single-nucleotide polymorphism, copy number and expression microarrays (Cancer Genome Atlas Research Network, 2008; Noushmehr et al., 2010; Verhaak et al., 2010) . A number of other microarray expression profiling studies on gliomas have also been published. These data sets enable the development of systems biological knowledge on the molecular and genetic regulatory networks in glioma.
In this study, we mined for glioma-specific genes from our GeneSapiens database that contains gene expression data from 9783 samples covering 175 types of healthy and pathological tissues (Kilpinen et al., 2008) . This database contains Affymetrix (Santa Clara, CA, USA) gene expression array experiments and makes it possible to compare mRNA expression levels of genes across different tissues. The database includes data from 425 histologically normal tissue samples from the central nervous system and 475 glioma samples (322 GBMs, 66 anaplastic astrocytomas, 10 astrocytomas, 44 anaplastic oligodendrogliomas, 15 oligodendrogliomas and 18 mixed gliomas). Here, we systemically sought for putative mRNA expression-based biomarkers in GBM and anaplastic astrocytoma and found that HES6 (hairy and enhancer of split 6) was highly expressed in gliomas as compared with the normal brain tissues.
HES6 is a member of the basic helix-loop-helix family of transcription factors. Its overexpression has been reported in metastatic colon and prostate cancers (Swearingen et al., 2003; Vias et al., 2008) , and in cancers of the lung, breast and kidney (Swearingen et al., 2003; Hartman et al., 2009 ). Hes6 inhibits Hes1 activity by forming heterodimers with Hes1, supports achaete-scute complex homolog-1 (Ascl1) activity and promotes neuronal differentiation (Bae et al., 2000; Koyano-Nakagawa et al., 2000) . During cortical neurogenesis and in the presence of astrocyte inducers ciliary neurotrophic factor or leukemia inhibitory factor, HES6 can prevent the precursor-to-astrocyte transition and promote neuronal differentiation through independent mechanisms (Jhas et al., 2006) . Progressive astrocytoma and secondary GBM formation are characterized by inhibition of Notch signaling; upregulation of DLL1, ASCL1 and HES6, and uninduced levels of HES1 (Somasundaram et al., 2005) . Here, we evaluated the role of HES6 as a potential biomarker in glioma and its functional importance.
Results
Systematic body-wide search for overexpressed genes in glioma from the GeneSapiens database We searched for potential biomarkers in anaplastic astrocytoma and GBM as compared with normal brain tissue on the basis of the genome-wide transcriptomics data in the GeneSapiens database (Kilpinen et al., 2008) . The expression of the identified genes was then evaluated across all normal and cancerous tissues. The genome-and body-wide mining implicated transcription cofactor HES6 as the most highly ranked gene in anaplastic astrocytoma, and with a rank number 10 in GBM. HES6 gene was highly expressed in gliomas as compared with both normal brain tissues, as well as with all other normal and cancer tissues (Figures 1a-c) . High HES6 expression was present in anaplastic astrocytoma, GBM, oligodendroglioma and mixed glioma (Figure 1c) . High HES6 mRNA expression in these tumor types (n ¼ 452) was also observed in the REpository for Molecular BRAin Neoplasia DaTa (Rembrandt) (Madhavan et al., 2009 ) when compared with the normal brain tissues (n ¼ 28; Supplementary File S1A). Neuroblastoma, melanoma, colon cancer and some breast cancers displayed slightly elevated expression of HES6 (Figure 1b) . In comparison, a body-wide expression plot for epidermal growth factor receptor (EGFR; Supplementary File S1B) showed high expression in glioma, as well as cancers of the lung, head and neck, thyroid, bladder and mesothelioma, in addition to several normal tissues. Out of the glioblastoma samples available in both GeneSapiens (Figure 1d ) and TCGA (Supplementary File S1C), high HES6 gene expression was associated with proneural tumors, whereas mesenchymal tumor types had the lowest expression levels.
HES6 protein expression in tumors HES6 protein levels were studied in a glioma tissue microarray (TMA) with 417 samples and in 9 normal brain tissue samples. Tumor HES6 expression could be assessed in 339 (81.3%) out of the 417 cases. HES6 expression was detected in 335 (98.8%) out of the 339 tumors regardless of glioma tumor histology (Table 1) . A total of 74 (21.8%) of the tumors showed low levels of HES6 expression ( þ ), 83 (24.3%) moderate ( þ þ ) and 178 (52.5%) strong expression ( þ þ þ ). Six out of the nine normal brain tissue samples were negative and three showed low HES6 staining. We also analyzed 30 nonglioma brain tumors, including medulloblastomas, meningiomas and schwannomas. Of these, 18 (60%) showed negative (À), 9 (30%) low ( þ ) and 3 (10%) moderate ( þ þ ) HES6 expression; none showed strong expression.
HES6 immunoreactivity in gliomas was mainly nuclear (Figure 2 ). Low-intensity cytoplasmic staining was seen in astrocytomas with gemistocytic cells (Figure 2e ). There was no statistical association between HES6 staining intensity, the histological tumor type or the WHO grade. HES6 staining of endothelial cells was present in 75% of glioma samples and in four out of nine samples of non-neoplastic cerebral white matter and cortex (arrows in Figure 2 ).
HES6 protein was expressed more strongly in tissue biopsies taken from recurrent brain tumors as compared with tissue collected at the time of first diagnosis (Table 1) . HES6 was expressed strongly ( þ þ þ ) in 12 (80%) out of the 15 recurrent astrocytomas as compared with 19 (54%) out of the 35 primary astrocytomas (P ¼ 0.039). Similarly, 11 (73%) out of the 15 recurrent oligodendrogliomas expressed HES6 strongly as compared with only 5 (29%) of the 17 primary oligodendrogliomas (P ¼ 0.013). In GBMs, no significant difference in HES6 expression was present between primary versus recurrent or primary versus secondary GBM tumors (P ¼ 0.745 and P ¼ 0.215, respectively).
Associations between HES6 protein expression with PDGFRA, KIT, VEGFR2 and EGFR gene copy numbers and protein levels Platelet-derived growth factor receptor alpha (PDGFRA), KIT, vascular endothelial growth factor receptor 2 (VEGFR2) and EGFR gene copy numbers were determined in a subset of patients (n ¼ 37) diagnosed with primary GBM using chromogenic in-situ hybridization (CISH) and compared with tumor HES6 expression. Presence of strong ( þ þ þ ) tumor HES6 expression was compared with less expression (À, þ or þ þ ). Amplifications of PDGFRA, KIT and VEGFR2, which are adjacent genes on chromosome 4q, were associated with strong tumor HES6 expression (Supplementary File S2A) . The association between amplified PDGFRA and HES6 expression was particularly strong. PDGFRA amplification was detected in 5 (19.2%) out of the 26 GBMs successfully analyzed, and 4 (80%) out of the 5 GBMs with strong HES6 expression had amplified PDGFRA (P ¼ 0.005; Supplementary File S2A). EGFR amplification or the total EGFR protein level was not associated with strong HES6 expression (P ¼ 0.693 and P ¼ 1.0, respectively), but HES6 expression was associated with expression of phosphorylated EGFR (P ¼ 0.022; Supplementary File S2B).
Tumor HES6 expression and survival in glioblastoma Association of tumor HES6 protein expression with survival was examined among patients diagnosed with either primary or secondary GBM. Survival information was available from 55 patients. The median time to death from the date of the diagnosis was 15 months, and all 55 patients eventually died from GBM. Tumor HES6 protein expression was not associated with overall survival when grouped in either three ( þ , þ þ or þ þ þ ) or in two categories ( þ and þ þ vs þ þ þ ; P ¼ 0.96 and P ¼ 0.79, respectively). In the Rembrandt database (Madhavan et al., 2009) , HES6 gene expression was not associated significantly with survival in GBM (P ¼ 0.290, n ¼ 181) or astrocytoma (P ¼ 0.069, n ¼ 105). However, in the large TCGA-GBM data set, high HES6 gene expression is associated with favorable survival in a Kaplan-Meier analysis with the Anduril tool (P ¼ 0.0354, n ¼ 348; Supplementary File S1D; Ovaska et al., 2010) . However, this survival difference can be linked to the different subgroups of GBM.
Functional importance of HES6 for glioma cell proliferation HES6 inhibits the cell proliferation when overexpressed in HeLa and mouse embryonic fibroblast cells (Eun et al., 2008 Genome-wide analysis of HES6 silencing and overexpression in glioma cell lines The effect of HES6 silencing on genome-wide gene expression was analyzed in the A172 and LN405 glioma cell lines. Expression levels of 265 genes were found to be consistently altered when the normalized ratios from both cell lines and from all HES6 siRNA treatments were subjected to rank-based meta-analysis (Supplementary File S4A). HES6 overexpression was analyzed in stably pEYFP-HES6-overexpressing LN405 cells and compared with pEYFP-mock cells. Expression of 372 genes was altered at least twofold after HES6 overexpression including increase in the progenitor cell marker nestin (Supplementary File S4B). When both HES6 silencing and overexpression data were analyzed using rank-based meta-analysis, expression of 88 genes was consistently the opposite in knockdown and knockin experiments (Figure 4 and Supplementary File S4C). These genes included neurotactin (CX3CL1), transforming growth factor-b receptor II (TGFBR2), Norrie disease (NDP) and nuclear factor (NF)-kB inhibitor-a (NFKBIA). Genes that were flagged by HES6 silencing, overexpression or both were analyzed with the Ingenuity Pathways Analysis (IPA, Ingenuity Systems Inc., Redwood City, CA, USA) and MetaCore (GeneGo Inc., St Joseph, MI, USA) programs. The most significant biological functions of the commonly deregulated genes included cellular movement, migration, invasion, adhesion, angiogenesis, development, cell-tocell signaling, cell proliferation, cell death and apoptosis (Table 2 , and Supplementary File S5).
Functional importance of HES6 for glioma cell migration As several of the HES6-deregulated genes were related to cell migration, a wound-healing assay was conducted using the U87MG cell line where HES6 silencing does not cause reduction in cell proliferation. HES6 silencing reduced wound closure and wound confluence, indicating inhibition of cell migration ( Figure 5 ).
HES6 as a transcriptional regulator/cofactor
The HES6-deregulated genes (listed in Supplementary File S4) were analyzed using the transcription regulation algorithm in MetaCore (GeneGo Inc.). Aberrant expression around key regulator genes, such as myelocytomatosis viral oncogene homolog (MYC), NF-kB and p53 was observed (Table 3 and Supplementary File S6). HES6 interacts in vitro with a specific type of E-box sequence, the ESE box (Jennings et al., 1999; Cossins et al., 2002) . Significant enrichment of several transcription factor motifs within the proximal regulatory regions of HES6-deregulated genes was apparent, including E-box, MYC, HES1, Sp1 transcription factor, hepatocyte nuclear factor 4 (HNF4), p53 and NF-kB (Supplementary File S7). Interestingly, the HES6 dimerization partner, HES1 (Bae et al., 2000) , binds to 10 out of the 20 key regulator genes identified (Table 3) . Furthermore, HES1 expression was reduced after HES6 silencing (Supplementary File S8).
HES6 localizes with promyelocytic leukemia protein and CREB-binding protein HES6 colocalizes and co-immunoprecipitates with the CREB-binding protein (CBP, also known as CREBBP) The percentages do not add up to 100 because of rounding. Nuclear staining of HES6 was scored semiquantitatively as:À (no staining), þ (1-5% positive nuclei), þ þ (6-10% positive nuclei) and þ þ þ (11-100% positive nuclei).
HES6 in glioma S Haapa-Paananen et al and the promyelocytic leukemia protein in the nuclear bodies in HeLa cells (Eun et al., 2008) . In line with this, we observed a speckle-like nuclear localization of HES6 in the A172 GBM cell line after transfection with the pEYFP-Hes6wt construct. Most of these speckles colocalized with the promyelocytic leukemia-nuclear bodies and CBP when co-stained with the respective antibodies (Supplementary File S9) . Notably, CBP is known to bind to 17 out of the 20 key regulator genes identified in this study (Table 3) . cAMP-response element binding (CREB) motifs were also enriched within the HES6-deregulated genes (Supplementary File S7).
HES6 and MYC
As the transcription regulation algorithm and the motif enrichment analyses pointed to MYC-responsive genes among the HES6-deregulated genes, we also analyzed MYC expression and promoter activity. In LN405 cells, MYC expression was increased significantly 24 h after HES6 silencing when assessed using quantitative real-time-PCR (P ¼ 0.0056, Figure 6a) . In U87MG cells, silencing of HES6 did not cause a significant change in MYC mRNA levels (data not shown), but a significant reduction of MYC promoter activity took place when measured using a MYC-luciferase reporter assay (P ¼ 0.0039, Figure 6b ). Thus, HES6 expression can modulate MYC expression and/or activity depending on the cell line context.
Discussion
On the basis of genome-and body-wide bioinformatics mining of the GeneSapiens database, HES6 turned out to be one of the most glioma-specific genes, showing overexpression in different histological subtypes of glioma as compared with normal brain tissues. This observation was confirmed in the Rembrandt data (Madhavan et al., 2009 HES6 in glioma S Haapa-Paananen et al HES6 protein expression has not been studied in clinical tumors. In our analysis, 98.8% of gliomas showed HES6 immunoreactivity and 52.5% of gliomas stained strongly, whereas the normal brain tissues stained weakly or not at all. In accordance with the mRNA expression levels, HES6 protein expression was not specific to any histological subtype of glioma. However, recurrent grade 2 astrocytomas and grade 2-3 oligodendrogliomas showed higher levels of HES6 immunoreactivity than the corresponding primary tumors. HES6 expression was present in endothelial cells in 75% of glioma samples, suggesting a potential role for this protein in angiogenesis.
Interestingly, high HES6 gene expression was evident in proneural tumors and its expression was low in mesenchymal subtypes of GBM. The proneural subtype is associated with more favorable survival as compared with the mesenchymal subtype (Cooper et al., 2010; Verhaak et al., 2010) , but the proneural tumors recur often and respond poorly to treatment (Verhaak et al., 2010) . In line with the association with the proneural subtype, high HES6 expression predicted better survival in the TCGA-GBM tumors (P ¼ 0.0354) and associated with tumor recurrence. HES6 expression is likely not useful for making a differential diagnosis among oligodendrogliomas, astrocytomas and GBMs, but it is a more general biomarker for gliomas.
Major molecular features in the proneural subtype include alterations of PDGFRA and isocitrate dehydrogenase 1 (IDH1) (Verhaak et al., 2010) . We found an association between strong tumor HES6 expression and amplifications of PDGFRA, KIT and VEGFR2. HES6 interaction partner CBP binds to the promoters of PDGFRA and VEGFR2 (Illi et al., 2000; Watson et al., 2002) , and we observed that the HES6 overexpression resulted in increase of PDGFRA and KIT expression (Supplementary File S4) . Additionally, 11 genes identified in HES6 perturbation experiments are proneural GBM signature genes (Verhaak et al., 2010) , including neural cell adhesion molecule 1 (NCAM1), SRY-box 11 (SOX11), contactin 1 (CNTN1), NK2 homeobox 2 (NKX2-2) and microtubule-associated protein 2 (MAP2). Strong HES6 expression did not correlate with EGFR gene amplification or increased EGFR protein expression, both of which are relatively specific for the classical GBM subtype. Taken together, these Cell proliferation was assayed 72 h after transfection using a CellTiter-Glo assay (mean ± s.e.m.). Statistically significant changes in panels c and e are shown with asterisks (*Po0.05, **Po0.01, ***Po0.001).
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HES6 likely has an important function in supporting the growth and survival of glioma cells. In vitro, silencing of HES6 inhibited cell proliferation in two GBM cell lines. In primary rat cortical neuron cell lines, overexpression of HES6 using a pEYFP-Hes6wt plasmid causes neuronal death and apoptosis via a p53-dependent pathway (Eun et al., 2010) . In the present study, transient HES6 overexpression using the pEYFP-HES6wt plasmid resulted in such a high overexpression that only glioma cells with modest pEYFPHES6wt (approximately 3-to 15-fold) expression survived as a stable cell line.
Gliomas are invasive brain tumors, and data from the HES6 perturbation experiments indicated enrichment in gene ontology categories related to adhesion, migration and invasion. This was supported by the observation that HES6 silencing inhibited migration of the U87MG cell line (Figure 5) . One of the HES6-deregulated genes, previously connected to migration and invasion, was TGFBR2 that suppresses glioma cell migration and invasion in vitro and reduces tumorigenicity in vivo after RNA interference (Naumann et al., 2008; Wesolowska et al., 2008) , and another one was the insulin-like growth factor-binding protein 2 (IGFBP2) that increases glioma cell migration (Wang et al., 2006) .
HES6 has been previously implicated in metastatic neuroendocrine prostate cancer, breast cancer and metastatic colon carcinoma (Swearingen et al., 2003; Vias et al., 2008; Hartman et al., 2009 ). In the GeneSapiens database, neuroblastoma, melanoma, colon cancer and some breast cancers display somewhat elevated expression of HES6, but it is 5-10 times higher in the gliomas. HES6 may also have a more general role in cancers. HES6 overexpression increases cell proliferation of MCF-7 breast cancer cells in vitro and in xenografts (Hartman et al., 2009) . From the genomewide gene expression profiling after HES6 perturbations, we found aberrant expression around several key transcriptional regulator genes. On the basis of chipon-chip data (Margolin et al., 2009) , HES1 is known to bind to 10 of the 20 key regulator genes found in our study. Of these key regulator genes, p53 and E2F1 have been linked to HES6 previously in other cell types than glioma (Eun et al., 2008 (Eun et al., , 2010 Hartman et al., 2009) . The motif enrichment analysis of the HES6-deregulated genes revealed significant enrichment of the same transcriptional regulator motifs, including E-box, MYC, CREB and HES1. HES6 is a transcriptional repressor of HES1 (Bae et al., 2000; Gratton et al., 2003) , and silencing of HES6 increased HES1 mRNA levels (Supplementary File S8). HES6 colocalizes with (Supplementary File S9) and also interacts with the CREB-binding protein (CREBBP; Eun et al., 2008) , which is a transcriptional co-activator and acts as a scaffold to stabilize additional protein interactions within the transcription complex. Silencing of HES6 and the consequent loss of HES6 from this complex could change expression around the 17 CREBBPinteracting key regulator genes listed in Table 3 , including MYC.
E-box and MYC motifs were enriched in the HES6-deregulated genes, and silencing of HES6 can affect MYC expression and activity depending on the cell context in vitro (Figure 6 ). On the basis of chip-on-chip data, MYC associates with the HES6 gene promoter Figure 4 Hierarchical clustering of the oppositely deregulated genes after HES6 silencing and overexpression. The R/Bioconductor package RankProd (Hong et al., 2006) was used to find genes that are regulated in an opposite way when HES6 is overexpressed (two replicates) or silenced (two replicates of siHES6 and a HES6_2 siRNA) in LN405 cell line. Hierarchical clustering was performed to display the data.
HES6 in glioma S Haapa-Paananen et al between HES6 and MYC. Nestin, a marker for neuronal stem cells/progenitors and a marker for poor prognosis in glioma (Strojnik et al., 2007; Schiffer et al., 2010) , is one of the E-box-containing genes that shows increased expression after HES6 overexpression. MYC overexpression has been reported to activate transcription of nestin and to repress GFAP, a marker of differentiated astrocytes, while promoting a more undifferentiated phenotype in mature murine astrocytes and GBM cells (Lassman et al., 2004; Panicker et al., 2010) . The transcriptional co-activator p300 mediates expression of GFAP and repression of MYC, but MYC overexpression can over-ride the p300-related effects. The p300 silencing increases GBM cell invasion and results in nestin induction (Panicker et al., 2010) . In the present study, HES6 silencing resulted in a decrease in MYC activity and reduced migration of U87MG cells. Currently, it is unknown whether HES6 interacts with MYC directly or indirectly within a nucleoprotein complex involving, for example, p300-CBP-CREB. Abbreviation: HES, hairy and enhancer of split 6.
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In the presence of gliogenic stimuli, HES6 overexpression increases nestin and decreases GFAP levels in cortical progenitor cells. HES6 expression prevents the precursor-to-astrocyte transition, resulting in an expansion of the neural progenitor cell pool (Jhas et al., 2006) . In glioma, HES6 overexpression might maintain the cancer stem cell population as suggested by the increase of nestin expression, although HES6 and nestin or CD133 protein levels were not associated in the current study.
We conclude that HES6 is a key molecular modulator in glioma that likely influences tumor growth and cell migration. HES6 is selectively and frequently overexpressed in glioma and is an important transcriptional regulator.
Materials and methods

Data mining from the GeneSapiens database
The GeneSapiens database contains gene expression data of 17 330 human genes in 9783 samples from 175 types of healthy and pathological tissues (Kilpinen et al., 2008) . This database is comprised of Affymetrix gene expression array experiments and allows evaluation of mRNA expression levels of most human genes across different tissues (http://www.genesapiens. org/). From this database (version 3), we systemically sought for putative mRNA expression-based biomarkers in GBM and anaplastic astrocytoma using a novel Gene Tissue Index algorithm (Mpindi et al., 2011) to detect outlier gene expression, that is, overexpression of a gene in a subset of the tumor samples.
Cell culture and reagents
Cell lines A172 and U87MG were obtained from ECACC (Salisbury, UK), LN405 from the DSMZ (Braunschweig, Germany) and SVG p12 from ATCC (Manassas, VA, USA). Cells were cultured in medium conditions recommended by the providers for less than 4 months before use in these experiments. Sequences for three siRNAs for HES6 and a control siRNA for PLK1 are described in supplementary materials. All siRNAs were purchased from Qiagen (Hilden, Germany). Additional control siRNAs were AllStars Hs Cell Death Control siRNA (Qiagen) and Negative Control siRNA (Qiagen). The siRNAs were used at a final concentration of 15 nM each, or as a pool of three siRNAs (denoted as siHES6) 10 nM each, thus giving a final concentration of 30 nM. LN405 cells were used for creating stable cell lines by transfecting pEYFP-C1-mock and pEYFP-C1-HES6 with Fugene6 (Roche Applied Science, Indianapolis, IN, USA) and selecting the positive cells with 600 mg/ml and maintained with 400 mg/ml of G418 (Sigma-Aldrich, St Louis, MO, USA).
Real-time quantitative PCR analysis
Total cellular RNA was isolated using a MiRVana Total RNA isolation kit (Ambion, Austin, TX, USA) or an RNeasy Mini kit (Qiagen). For complementary DNA synthesis, 200 ng of RNA was reverse transcribed with High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). The complementary DNA was diluted 1:2 and the Taqman quantitative real-time-PCR analysis was performed with an Applied Biosystems 7900HT instrument using specific primers for HES6, HES1, MYC, glyceraldehyde 3-phosphate dehydrogenase and actin beta (ACTB) designed with the Universal Probe Library Assay Design Center (Roche Applied Science). The sequences of the primers are described in supplementary materials. The fluorescent Taqman probes were obtained from Roche Human Probe Library. The results were analyzed with SDS 2.3 and RQ manager software (Applied Biosystems), and expression of HES6, MYC or HES1 mRNA was determined by relative quantification method using ACTB or glyceraldehyde 3-phosphate dehydrogenase as an endogenous control. The data were collected from 2-3 separate biological experiments, which were run twice in quadruplicates.
Immunohistochemistry Formalin-fixed, paraffin-embedded tissues from 417 brain tumors of patients who underwent craniotomy for a primary or recurrent glioma in 1979-2003 were retrieved from the archives of the Department of Pathology, Helsinki University Central Hospital, Finland, as described previously (Joensuu et al., 2005; Puputti et al., 2006) and from the Department of Pathology, Tampere University Hospital (Haapasalo et al., 2006) , for construction of a TMA (Table 1) . Whole-tissue sections of histologically normal brain tissue (n ¼ 9) were analyzed. For detailed description of the TMA construction, see supplementary materials and methods.
Five-micrometer sections were cut for HES6 immunohistochemistry. HES6 expression was analyzed on tumor TMA, and non-tumor and normal whole-tissue sections. HES6 was detected with a synthetic peptide derived from the C terminus HES6 immunoreactivity in TMA samples was evaluated by two pathologists (HH and OT) using a consultation microscope (Nikon Eclipse E600, Nikon Instech Co., Kanagawa, Japan). Nuclear staining of HES6 in tumor cells in wholetissue core area (0.28 mm 2 or 0.79 mm 2 ) was scored semiquantitatively by consensus of the two investigators as: 0 (no staining), 1 (1-5% positive nuclei), 2 (6-10% positive nuclei) or 3 (11-100% positive nuclei). Endothelial cell immunoreactivity was classified as either negative or positive (staining in one or more nuclei).
Proliferation assays
Cell proliferation was assayed with a CellTiter-Glo Cell Viability assay (Promega, Madison, WI, USA). The signals were quantified using an Envision Multilabel Plate Reader (Perkin-Elmer, Massachusetts, MA, USA). Cell growth and confluence was monitored by taking time-lapse phase-contrast images once per hour from cells grown for 3 days in a CO 2 incubator using an IncuCyteHD microscope (Essen Instruments Inc.).
Wound assay U87MG cells (150 000 cells/well) were reverse transfected with 30 nM siHES6 or negative control siRNA using SiLentFect in 24-well Image Lock plates (Essen Instruments Inc.). Wounds were generated next day by scratching with a 24-well Wound maker tool (Essen Instruments Inc.). Wound closure and confluence was monitored by taking time-lapse phase-contrast images (3 images/well) once per hour of live cells grown for 30 hr in a CO 2 incubator with an IncuCyteHD microscope (Essen Instruments Inc.).
Illumina gene expression and data analyses A172 and LN405 cells (240 000/well on six-well plates) were transfected for 12 h with a siHES6 pool, three individual siRNAs or negative control siRNA at 30 nM using SiLentFect (Bio-Rad Laboratories, Hercules, CA, USA). One to two biological replicate transfections were performed. Total RNA was isolated with an RNeasy kit (Qiagen). RNA quality was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). In all, 300 ng of purified total RNA was amplified with an Illumina Total Prep RNA Amplification kit (Illumina, San Diego, CA, USA), and 750 ng of biotin-labeled complementary RNA was hybridized to Sentrix HumanHT-12 v3 Expression BeadChips (Illumina) at the Finnish DNA Microarray Centre, Turku Centre for Biotechnology. The arrays were scanned with an Illumina BeadArray Reader, and raw data were produced using a GenomeStudio (Illumina). The microarray data have been deposited in the NCBI's Gene Expression Omnibus and is accessible through a GEO Series accession number GSE22692. The Illumina data analyses are described in detail in the supplementary methods.
MYC-luciferase reporter assay
The activity of Myc-regulated signals transduction pathways were assessed using a Cignal MYC reporter assay kit (SABiosciences, Qiagen) according to the manual. In brief, U87MG cells (20 000/well) were co-transfected either with 100 ng of (1) an inducible MYC-responsive firefly luciferase after HES6 silencing. LN405 glioblastoma cell line was transfected with 30 nM siHES6 or negative control siRNA (siNEG), and incubated for 24 or 48 h. Thereafter, the total cellular RNA was isolated and analyzed with Taqman quantitative real-time-PCR for the expression of MYC and HES6 mRNA. The results normalized for ACTB are shown as relative expression using siNEG as a reference. Statistically significant changes are shown with asterisks (**Po0.01, ***Po0.001, n ¼ 5 biological repeats). (b) A firefly luciferase MYC reporter assay was used to measure the MYC transcription promoter activity when HES6 was silenced. The U87MG cells were co-transfected using Lipofectamine2000 with MYC reporter or negative control, together with 30 nM siHES6 or siNEG. Luciferase activity was measured after 48 h incubation with Dual-Glo Luciferase assay. The MYC promoter activity is expressed as arbitrary units using a renilla reporter for internal normalization. Results are averages of three separate experiments, each conducted in triplicate ( þ /Às.e.m., **Po0.01).
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